Clinical trial · Observational
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.
Stage IV Breast Cancer Gene Expression Control Using Micro-Trace and Plant Extracted Natural G.R.A.S. (Generally Accepted As Safe), Compounds in Adjunct Therapy Alongside Conventional Cancer Protocols
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Plant extracted natural compounds, in an adjunct therapy position, slow the growth and reproduction of Stage IV Breast Cancer tumor cells. May help eradicate different types of cancers. PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using natural plant extracted compounds, G.R.A.S. (Generally Accepted As Safe), compounds, the reproduction, growth progress and metastasis of Stage IV Breast Cancer cells. The therapy position is adjunct to conventional therapies and in "one-off" trials have been excitingly effective for long-term survival. Novel use of bioactive GRAS compounds to augment and enhance conventional cancer therapies and as stand-alone parallel therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| therapeutic dietary intervention | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Arm I
- description
- Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
- interventionNames
- Other: laboratory biomarker analysis
- Procedure: therapeutic dietary intervention
- label
- Arm II
- description
- Patients do not receive supplements.
- interventionNames
- Other: laboratory biomarker analysis
Primary outcomes (4)
- measure
- Utilize GRAS plant extracted compounds for suppression of cancer-cell replication.
- timeFrame
- 12 months
- description
- Using adjunct therapy to augment and increase efficacy of conventional cancer treatments
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of prostate, breast, or uterine cancer * Early or late stage disease * Currently waiting to initiate conventional therapy or radiotherapy OR receiving concurrent conventional chemotherapy or radiation therapy * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior or concurrent chemotherapy or hormonal therapy for cancer allowed
References
Publications (0)
Data not yet available